Brief: Terns Pharmaceuticals Reports Topline 12-Week Data From Its Phase 2 Trial Evaluating Oral Glp-1 Receptor Agonist Tern-601 In Obesity

Terns Pharmaceuticals

21/10/2025 21:57

Oct 21 (Reuters) - Terns Pharmaceuticals Inc TERN.O:

TERNS PHARMACEUTICALS REPORTS TOPLINE 12-WEEK DATA FROM ITS PHASE 2 TRIAL EVALUATING ORAL GLP-1 RECEPTOR AGONIST TERN-601 IN OBESITY

TERNS PHARMACEUTICALS INC: WILL NOT ADVANCE TERN-601 OR INVEST IN OTHER METABOLIC ASSETS

TERNS PHARMACEUTICALS INC: RESULTS SHOW MAXIMUM PLACEBO-ADJUSTED WEIGHT LOSS OF 4.6% WITH 12% TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS

TERNS PHARMACEUTICALS: ASYMPTOMATIC, REVERSIBLE GRADE 3 LIVER ENZYME ELEVATIONS OCCURRED IN THREE PARTICIPANTS DURING POST-TREATMENT FOLLOW-UP PERIOD

TERNS PHARMACEUTICALS INC: TWO OF THE ASYMPTOMATIC, REVERSIBLE GRADE 3 LIVER ENZYME ELEVATIONS THAT OCCURRED IN PARTICIPANTS WERE DEEMED DRUG RELATED

Source text: ID:nGNX4KlfZS

Further company coverage: TERN.O

 ((Reuters.Briefs@thomsonreuters.com;))